Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Randy Burkholder

Randy Burkholder Randy Burkholder is a former Vice President of Policy and Research at PhRMA. He has over 17 years experience in health care policy, advocacy and communications in the medical technology and pharmaceutical industries.

Recent Posts

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

By Randy Burkholder  |    July 24, 2018
If a home inspector found “wide and unpredictable variation” in your smoke detectors, would you want to fix them?   Read More

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

By Randy Burkholder  |    June 1, 2018
In health care, who should decide value? In many industrialized countries with single-payer health systems, the answer is “the government.” A new analysis by Avalere illustrates the negative impact...   Read More

Improving care quality by engaging patients in shared decision making

By Randy Burkholder  |    March 22, 2018
With the rapid movement towards value-based payment and delivery in health care, it is critical not to leave one of the key players behind: the patient.     Read More

ICYMI: ICER solicits feedback on its value assessment framework

By Randy Burkholder  |    July 28, 2016
In case you missed it, the Institute for Clinical and Economic Review (ICER) is seeking suggestions to improve its value assessment framework prior to its re-release in 2017. For the past two years,...   Read More

A shared commitment to value

By Randy Burkholder  |    November 9, 2015
Last week, the New England Journal of Medicine published a perspective from PhRMA’s Dr. Bill Chin alongside a counterpoint by Dr. Peter Bach, and I was struck by the extent to which both pieces...   Read More

Value at the crossroads, part II

By Randy Burkholder  |    September 8, 2015
Value assessment in health care continues to generate considerable interest, as reflected in the wide range of comments sent to the American Society of Clinical Oncology (ASCO) on their Value...   Read More

Outdated FDA Regulations Discourage Development and Dissemination of Healthcare Economic Data to Support Value-Based Healthcare

By Randy Burkholder  |    July 2, 2015
As demand for evidence about the clinical and economic benefits of new treatments continues to grow, Food and Drug Administration (FDA) regulations on communications by biopharmaceutical companies...   Read More

ASCO’s Framework: Value at the Crossroads

By Randy Burkholder  |    June 23, 2015
Yesterday the American Society of Clinical Oncology (ASCO) released its long-awaited draft conceptual framework to assess the value of cancer treatment options. PhRMA has long supported the...   Read More

New Research Highlights Gaps in Quality Measures for Cancer Patients

By Randy Burkholder  |    June 1, 2015
This weekend marked the start of the annual meeting of The American Society of Clinical Oncology (ASCO).  This year’s meeting, which features a theme of “Innovation and Illumination,” highlights the...   Read More

Paving the Way for Better Cancer Treatments

By Randy Burkholder  |    April 8, 2015
Last week, during Ken Burns’ documentary, Cancer: The Emperor of All Maladies, Americans heard about the scientific community’s decades-long, tireless fight to treat and cure cancer, an incredibly...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates